A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

STATUS

Recruiting
participants needed

18
sponsor

Hepion Pharmaceuticals, Inc.

Send

Updated on 19 February 2024

See if I qualify

fibrosis

hepatic fibrosis

fatty liver

fibroscan

vcte

Summary

Show definitions

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

Description

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects. Study will evaluate the safety and tolerability of a once daily 75mg dose of CRV431 compared to placebo over 28 days of dosing. Pharmacokinetic parameters of CRV431 and its major metabolites and fraction unbound will also be evaluated. Non-invasive antifibrotic bio-markers will be collected and quantified from presumed NASH F2/F3 subjects dosed with 75mg CRV431 or placebo.

Details

Condition	Cirrhosis, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Age	18years - 75years
Treatment	Placebo, CRV431
Clinical Study Identifier	NCT04480710
Sponsor	Hepion Pharmaceuticals, Inc.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male or female between 18 and 75 years of age (inclusive)
	Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel
	Presumed F2/F3 NASH to include: AST >20 IU/L, Pro-C3 >15.5 ng/mL, enhanced liver fibrosis (ELF) score >9.8, and FibroScan >8.5 kPa values
Exclusion Criteria
	Pregnant or breastfeeding or planning to become pregnant during the study period
	Known allergy to CRV431, cyclosporine, or any of their inactive ingredients
	Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus antibodies (HIVAb)
	Well documented causes of chronic liver disease according to standard diagnostic procedures to include any history or presence of decompensated cirrhosis
	Subjects with a platelet count <150,000/mL
	Subjects with hemoglobin A1c(HbA1c) >9.5%
	Weight loss of more than 5% within 3 months prior to randomization
	Subjects with a blood pressure to include a systolic pressure >150 or a diastolic pressure >90\
	At Screening, an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 mL (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method) and/or a Kidney Disease Improving Global Outcomes (KDIGO) category of >G2
	Subjects with a history of organ transplantation. Corneal transplantation will be allowed

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects